Compare APAM & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APAM | ADPT |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2011 | 2019 |
| Metric | APAM | ADPT |
|---|---|---|
| Price | $36.18 | $21.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $43.00 | $17.78 |
| AVG Volume (30 Days) | 853.5K | ★ 4.0M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 10.81% | N/A |
| EPS Growth | 10.66 | ★ 63.89 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $1,196,688,000.00 | $276,976,000.00 |
| Revenue This Year | $5.96 | $3.98 |
| Revenue Next Year | $5.05 | $22.72 |
| P/E Ratio | $46.59 | ★ N/A |
| Revenue Growth | 7.63 | ★ 54.77 |
| 52 Week Low | $33.96 | $9.96 |
| 52 Week High | $48.46 | $22.80 |
| Indicator | APAM | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 53.98 | 67.51 |
| Support Level | $35.20 | $15.08 |
| Resistance Level | $38.07 | N/A |
| Average True Range (ATR) | 0.95 | 1.16 |
| MACD | 0.07 | 0.26 |
| Stochastic Oscillator | 78.94 | 79.42 |
Artisan Partners Asset Management Inc is a investment management firm providing a range of investment strategies to a diverse group of clients around the world. Each of the company's strategies is managed by one of its several investment teams. Investment management services are offered to institutions through separate accounts and mutual funds. Artisan's investment offerings include several long-only, equity investment strategies across a multitude of market capitalization segments and investing styles in both the United States and international markets. The company operates as one segment in the investment management business. The company generates maximum portion of its revenues from clients domiciled in countries outside the United States.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.